Enzyme Immobilization Patents: Who Holds the Carrier and Crosslinking Claims
Filing peaked in 2021 at 35 records, then fell 69% to 11 by 2024 the last year the data can treat as complete — a sharp pullback from the post-pandemic bioprocessing push, not a signal that the field is exhausted. Filings rose from 19 in 2017 to a peak of 35 in 2021, then fell to 11 by 2024 — a 69% drop over that three-year span. 2025 and 2026 figures are still filling in, since publication lags filing by roughly 18 months, so this pullback should be read against 2024 as the most recent complete year rather than against the partial final years.
- 1MEDTRONIC MINIMED INC62
- 2OMNIBRX BIOTECHNOLOGIES PTE LTD31
- 3F HOFFMANN LA ROCHE & CO AG25
- 4ZYMTRONIX CATALYTIC SYSTEMS INC23
- 5RGT UNIV OF CALIFORNIA22
See the full enzyme immobilization technologies analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
How many enzyme immobilization patent families are there?
This dataset counts 717 published records filed or published between 2015 and mid-2026 that combine an immobilization method (carrier-bound, crosslinked aggregate, etc.) with an operational-stability term such as leaching, diffusion limitation or reuse cycles. The assignee ranking treats each of these 717 as a family, so the figure already accounts for related continuations within a single organization. It does not include every patent that mentions an enzyme carrier in passing — only records where the combination of immobilization and stability language appears together.
Who are the leading patent holders in enzyme immobilization?
The leading assignee holds 62 of the 717 records in scope, with the fifth-ranked holder at 22 and the tenth at 16. Combined, the top 5 assignees account for 22.7% of all 717 records and the top 10 for 35.8%, meaning the majority of filings are spread across a long tail of organizations with only a handful of records each. That pattern favors a new entrant checking specific claim language over one company's entire portfolio, since no single filer dominates the space.
Is enzyme immobilization patent filing growing or slowing?
Filing peaked in 2021 at 35 records and had fallen to 11 by 2024, a 69% decline over that three-year span — 2024 is the most recent year the dataset can treat as complete. Years after 2024 show lower counts too, but publication typically lags filing by around 18 months, so those later years are still filling in and should not be read as continued decline yet. The honest read is a real pullback from a 2021 peak, with the trend for 2025-2026 not yet resolved.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Enzyme Immobilization Technologies covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.